$22.5MRound, 4 November 2026
Biograil closed a €20 million round backed by Verve Ventures, Megatrend Invest and HTGF Opportunity to advance its oral drug delivery technology toward clinical development.
Update 4 November 2026 Closes the financing after an €8.5 million first close announced in July 2025, with HTGF Opportunity participating. eu-startups.com
- Amount
- $22.5M
- Announced
- 4 November 2026
- Investors
- Verve Ventures, Megatrend Invest, HTGF Opportunity growth fund
- Use of funds
- Supporting planned Phase 1 clinical testing of BIONDD, including GLP studies and GMP manufacturing process setup.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Biograil Raises €20M in Funding - FinSMEs FinSMEs
Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injection eu-startups.com